The Biology of Alkylating-Agent Cellular Injury

https://doi.org/10.1016/S0889-8588(18)30243-0Get rights and content

Alkylating agents, such as nitrogen mustard, cyclophosphamide, and the nitrosoureas, have been used to treat many malignancies for more than 30 years. It is now clear that they are not only cytotoxic but also mutagenic and carcinogenic. The initial alkylation event, monoadduct formation on ring nitrogens or extra-cyclic oxygens of nucleotide bases, can result in chromosomal loss or single base mutation, both of which can lead to malignant transformation. The bone marrow is particularly sensitive to these events, and acute myelogenous leukemia is the most common malignancy caused by alkylating agents. Mechanisms of genetic damage and mutagenesis are discussed.

References (0)

Cited by (53)

  • New strategies in microbial screening for novel chemotherapeutics

    2022, Bioprospecting of Microbial Diversity: Challenges and Applications in Biochemical Industry, Agriculture and Environment Protection
  • Selective sensitization of tumors to chemotherapy by marine-derived lipids: A review

    2013, Cancer Treatment Reviews
    Citation Excerpt :

    It is assumed that the toxicity of chemotherapy to normal tissues is due to its non-selective distribution to tissues, and is driven by mechanisms similar to those responsible for its toxicity to tumors. DHA or EPA enhance the antitumor activity of 15 anticancer drugs which represent six families of drugs: antimetabolites (5-FU and cytarabine),92,93 alkylating (cyclophosphamide, mitomycin-C and cisplatin)94–96 or intercalating agents (doxorubicin, epirubicin, irinotecan and mitoxantrone),97–99 microtubule stabilizers (vinorelbine, vincristine, docetaxel, paclitaxel),100–102 Abl tyrosine kinase inhibitor (imatinib)103 and arsenic trioxide.104 Most of these drugs have damaging effects on the DNA.

  • Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL-experience of the German Hodgkin's lymphoma study group analyzed by a parametric model of carcinogenesis

    2011, Annals of Oncology
    Citation Excerpt :

    Increased incidence of secondary AML/MDS is clearly related to the primary chemotherapy [10–14]. The AML/MDS-inducing effect of chemotherapy is assumed to be based on DNA-breaking alkylating agents (e.g. cyclophosphamide, procarbazine) and Topoisomerase II inhibitors (e.g. doxorubicin, etoposide) while the effect of RT is less clear [10, 11, 15–18]. Several study groups assessed the long-term incidence of AML/MDS for different primary therapies of Hodgkin's lymphoma (see [19, 20] for an overview and meta-analysis).

  • Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: The Arkansas experience in more than 3000 patients treated since 1989

    2008, Blood
    Citation Excerpt :

    Long-term sequelae are uncommon, so that even third and fourth transplants have been successfully applied.7,8 Myelodysplastic syndrome (MDS) is a well-recognized complication of cancer therapy, especially with hematopoietic stem cell–toxic therapies such as ionizing radiation and alkylating agent–based chemotherapy (melphalan, nitrosoureas), occurring a median of 4 to 5 years after treatment.9TTT–11 Whereas cytogenetic abnormalities typifying MDS (MDS-CAs) after alkylator-based therapy include partial or complete deletions of chromosomes 5, 7, and 20 as well as trisomy 8,12,13 topoisomerase inhibitors, etoposide and doxorubicin, target chromosome 11 and induce MDS with a shorter latency phase of 1 to 2 years.14TTT–16

View all citing articles on Scopus
View full text